Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Jennifer Amengual, MD, Columbia University
Conference Coverage
Exploring Treatment Strategies for Elderly Patients With Aggressive Lymphoma Ineligible for CAR T-Cell Therapy
03/11/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia &...
03/11/2024
Lymphoma, Leukemia & Myeloma Network
Jennifer Amengual, MD, Columbia University
Conference Coverage
Exploring Treatment Strategies for Elderly Patients With Aggressive Lymphoma Ineligible for CAR T-Cell Therapy
03/11/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia &...
03/11/2024
Lymphoma, Leukemia & Myeloma Network
Jennifer Amengual, MD, Columbia University
Conference Coverage
Exploring Treatment Strategies for Elderly Patients With Aggressive Lymphoma Ineligible for CAR T-Cell Therapy
03/11/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia &...
03/11/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD
Conference Coverage
Evaluating Chemo-Free Novel Agent Combination Therapies for Mantle Cell Lymphoma
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses the introduction of chemotherapy-free novel agents for the treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses the introduction of chemotherapy-free novel agents for the treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD
Conference Coverage
Evaluating Chemo-Free Novel Agent Combination Therapies for Mantle Cell Lymphoma
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses the introduction of chemotherapy-free novel agents for the treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses the introduction of chemotherapy-free novel agents for the treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD
Conference Coverage
Use of BTK Inhibitors in the First-Line Mantle Cell Lymphoma Treatment Landscape
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, provides insight into the use of BTK inhibitors in the frontline mantle cell lymphoma treatment space.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, provides insight into the use of BTK inhibitors in the frontline mantle cell lymphoma treatment space.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD
Conference Coverage
Use of BTK Inhibitors in the First-Line Mantle Cell Lymphoma Treatment Landscape
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, provides insight into the use of BTK inhibitors in the frontline mantle cell lymphoma treatment space.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, provides insight into the use of BTK inhibitors in the frontline mantle cell lymphoma treatment space.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD
Conference Coverage
Advances in Chemoimmunotherapy for Frontline Mantle Cell Lymphoma Treatment
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD
Conference Coverage
Advances in Chemoimmunotherapy for Frontline Mantle Cell Lymphoma Treatment
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Nicole Lamanna, MD
Conference Coverage
Exploring Potential Options for Treating Patients With Chronic Lymphocytic Leukemia With Pirtobrutinib
02/29/2024

Featuring Nicole Lamanna, MD

Featuring Nicole Lamanna, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia &...
02/29/2024
Lymphoma, Leukemia & Myeloma Network

Advertisement

About

For nearly 2 decades, the Lymphoma, Leukemia & Myeloma Congress (formerly the Lymphoma & Myeloma Congress) has been recognized around the world as the most respected forum for industry-leading hematologic research.

It’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use